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Abstract 
Breathlessness or “shortness of breath”, medically termed dyspnoea, remains a devastating 
problem for many people and those who care for them. As a treatment intervention, 
administration of opioids to relieve breathlessness is an area where progress has been made 
with the development of an evidence base. As evidence in support of opioids has 
accumulated, so has our collective understanding about trial methodology, research 
collaboration and infrastructure that is crucial to generate reliable research results for 
palliative care clinical settings.  
Analysis of achievements to date and what it takes to accomplish these studies provides 
important insights into knowledge gaps needing further research as well as practical insight 
into design of pharmacological and non-pharmacological intervention trials in breathlessness 
and palliative care.  
This paper presents current understanding of opioids for treating breathlessness, what is still 
unknown as priorities for future research and highlights methodological issues for 
consideration in planned studies.   
Words: 147 
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Introduction 
 
Breathlessness or “shortness of breath”, medically termed dyspnoea, remains a devastating 
problem for many people and those who care for them. It is frequently dismissed by both 
those that suffer from it as an inevitable part of growing older or as self-induced, and by 
clinicians who consider it intractable. Thus, the symptom has been described as 
“invisible”(1). However the past decade has seen headway regarding understanding of the 
link between pathophysiology and the genesis of breathlessness, pharmacological treatments, 
and non-pharmacological interventions. 
 
Several drivers have contributed to breathlessness coming into view in research and 
clinically. Firstly, chronic obstructive pulmonary disease (COPD) research has increasingly 
focussed on symptoms and symptom improvement, largely because treatments that lead to 
improvement in survival are few. Secondly, there has been inequitable access to palliative 
care services for people with non-malignant disease as highlighted by powerful patient voices 
describing their experience and the impact of the symptom on the realities of daily living(2-
5), as well as comparable symptom burden(6-11). Thirdly, breathlessness has been described 
as, “the pain of non-malignant disease;” the conceptual similarities between pain and 
breathlessness, the “total” experience affecting all domains of life, and the pathophysiology 
of the symptoms and their response to treatment are remarkably similar, with observations 
supported by neuroimaging and clinical studies (12;13). 
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People at the end of life want to participate in research that will improve the quality of care 
(14).  As a treatment intervention, administration of opioids to relieve breathlessness is an 
area where progress has been made. As evidence in support of opioids has accumulated, so 
has our collective understanding about trial methodology, research collaboration and 
infrastructure that is crucial to generate reliable research results for palliative care clinical 
settings(15-17). Methodologically rigorous research is imperative and achievable, so that 
people, often frail, do not give valuable time to projects that do not meaningfully contribute 
to the evidence base(18). It is important that the energy spent is not wasted on failed, 
underpowered or inadequately designed studies that do not provide the answers vitally 
needed to inform clinical decision-making.  
 
Analysis of achievements to date and what it takes to accomplish these studies provides 
important insights into evidence gaps needing further research as well as practical insight into 
design of pharmacological and non-pharmacological intervention trials in breathlessness and 
palliative care. This paper presents current understanding of opioids for treating 
breathlessness, highlighting what is still unknown.  Sections explicitly divide between the 
known and areas for exploration, however, it is acknowledged that areas with clear evidence 
are incomplete and that areas described as “unknown” incorporate unfolding insights.  
Suggestions of study designs required to address remaining questions are presented. 
 
(Insert Table 1 here; (10;19-26)) 
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What do we know? 
 
 
1. Efficacy  
A Cochrane review concluded that regular morphine, diamorphine and dihydrocodeine 
improved the sensation of chronic refractory breathlessness by a statistically and clinically 
significant effect size (19).  
An adequately powered placebo controlled study of oral morphine published the following 
year confirmed this finding, improving morning breathlessness intensity by a statistically and 
clinically significant 6.6mm and evening breathlessness by 9.5mm on a 0-100mm visual 
analogue scale (VAS). This was a 13- 19% improvement upon the participants’ average 
baseline refractory dyspnoea measurement of 50mm on a 100mm VAS .Participants had a 
variety of underlying aetiologies, mainly COPD (20).  
Further systematic reviews in cancer patients only, assessing the efficacy of morphine for 
breathlessness have supported the use of oral and parenteral morphine (27-29). 
 
2. Effective routes of administration (oral, parenteral) 
 
The Cochrane review conclusions were related to parenteral or oral administration of regular 
low-dose opioids which included morphine, diamorphine or dihydrocodeine but stated there 
was no evidence to support currently the use of nebulised opioids although studies were short 
term and under powered(19).  As such, an adequately designed and executed trial of 
nebulised opioids is required before a benefit from nebulised opioids can be excluded. 
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Since then, there have been several more studies of nebulised opioids (fentanyl, morphine 
and hydromorphone), (17;30-34) the results of which follow a pattern according to study 
design. Randomised studies that measured dyspnoea (two with morphine, and one with 
hydromorphone) had negative findings (30;33;34), but the small observational cohort of 
nebulised fentanyl  (n-=35) showed benefit (31), as did the single case report (32). 
Unfortunately, the placebo controlled randomised trial of fentanyl failed to recruit (17). 
Likewise, case series of intranasal and transmucosal routes of fentanyl administration have 
shown benefit (35-37). Given that the genesis of breathlessness is multi-factorial, it is not 
surprising that benefit seen in uncontrolled studies may reduce or disappear when trials are 
blinded and randomised, for example, using “before and after” comparisons can exaggerate 
treatment effects by 61% compared with controlled studies(38).  
 
3. Safety and tolerability  
 
In a two stage dose –titration (83 participants: 54% COPD; 29% primary lung cancer; 12% 
interstitial lung disease; 5% other causes), and pharmacovigilance (52 participants) open 
labelled study, opioid-naïve people with multi-aetiology dyspnoea were titrated daily from 10 
to 30mg daily sustained-relief morphine according to clinical benefit and study algorithm 
(10).  Patients were treated with weekly dose increments until effect and then long term on 
the dose (if any) resulting in clinical benefit.  This study provided more than 30 patient-years 
of data.  On an intention-to-treat basis, the response rate at the end of the dose-titration period 
was 52/83 (63%), giving a number needed to treat of 1.6; taking into account unacceptable 
side effects, the number needed to harm was 4.6. Of those who responded, 93% had done so 
by a dose of 20mg daily. In the pharmacovigilance phase, 14/52 stopped morphine due to 
unacceptable side-effects; constipation being the most common reason (6 people). There were 
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no episodes of respiratory depression or hospital admissions due to sustained-release 
morphine in either phase. 
 
4. Minimal change in efficacy required for patient-defined benefit (minimal clinically 
important difference) 
 
Using calculated mathematical models based upon people with chronic breathlessness due to 
COPD, Ries concludes that a minimally clinically important difference (MCID) is a change 
of 1 point in the Borg scale and 10 – 20mm on a VAS (23).  A consensus statement confirms 
this recommendation and expands it to cover all aetiologies, indicating that a 1 point 
improvement in the Borg score and 10mm on a VAS is a MCID (22). Recently, emerging 
data from a population of heart failure patients with chronic breathlessness has suggested that 
between 0.5 and 2.0 improvement in a 0-10 numerical rating scale (NRS) is meaningful, 
equating to a one point change on the global impression of change in breathlessness scale 
(unpublished data calculation from Oxberry S. Thesis: Opioids in Heart Failure. University of 
York 2010). MCID in chronic breathlessness is markedly different to the MCID in acute 
breathlessness. Data demonstrate that for acute breathlessness an improvement of 2 on a 0-10 
NRS is the MCID and probably reflects the qualitatively different experiences of both 
situations (39;40). 
Therefore, morphine’s impact of approximately 1 on a NRS (10mm on a VAS) or more is 
consistent with calculated and patient-defined MCID for chronic breathlessness (20;21).  
Even seemingly small changes identified in the efficacy studies lead to clinically important 
improvement.  However, recommendations continue to highlight that patient-rated variables 
should be included in studies to confirm patient-defined clinical impact and how it correlates 
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with differences in dyspnoea rating scores (e.g., patient reported global benefit of the 
intervention, patient preference for the intervention). 
 
5. Definition of a central mechanism of action 
 
The mechanisms whereby opioids help the sensation of breathlessness are not fully clarified, 
but there is progress in our understanding.  Opioid receptors and endogenous opioids are 
found throughout the cardiorespiratory system and endogenous opioid release forms part of 
the complex neuroendocrine response in heart failure, a syndrome characterised by chronic 
and acute-on-chronic dyspnoea (41-43). A recent RCT in COPD patients showed worse 
dyspnoea after treadmill exercise in those given naloxone (a centrally and peripherally acting 
opioid antagonist) compared with placebo confirming that endogenous opioids mediate the 
sensation of breathlessness (24). Animal and human studies suggest mechanisms whereby 
opioids may ease dyspnoea. Sympathetic stimulation and endogenous opioid production 
appear to be interlinked in a complex manner involving both central and peripheral 
mechanisms. Opioid receptor agonism may inhibit sympathetic drive by reducing 
intracellular cAMP, in the periphery, where this mechanism has been demonstrated in the 
myocardium (44;45). Down-regulation of peripheral chemoceptors may also reduce 
ventilatory drive and thus reduce sympathetic outflow (46).  
In addition to these mechanisms, neuro-imaging study groups are starting to apply the 
knowledge gained from work with functional magnetic resonance imaging (fMRI) in pain to 
breathlessness (13;25;47-51). The integrated cortical and sub-cortical network found to be 
involved in the perception of breathlessness induced in normal volunteers is strikingly similar 
to that involved in the perception of pain, especially within the context of the role of emotion 
and higher order cognitive functioning. It has been more challenging to study the functional 
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neuroimaging of people with chronic breathlessness due to pathology because it is more 
difficult for them to tolerate fMRI. However there is one study of people with chronic asthma 
that demonstrates some evidence of down regulation of the anterior insula, the area thought to 
be integrally related to perception of “unpleasantness” (50).  This is in keeping with the 
smaller MCID for chronic breathlessness than for acute breathlessness, although this study 
did not apply the same resistive load to patients and normal controls. 
In initial work with opioids and fMRI in induced breathlessness in normal volunteers using 
breath holding as a model of inducing “urge to breathe” by Pattinson and colleagues has 
shown that ramifentanil is able to decrease localised breathhold related “urge to breathe” 
activity in the left anterior insula and operculum in conjunction with a corresponding 
dramatic reduction in the participant’s awareness of respiration (52). Motor and sensory 
activities, however were largely unaffected by ramifentanil. 
 
 
What is there to find out? 
 
1. Is there a class effect from opioids? Do mu opioid agonists deliver the most benefit? 
 
In general, open label observational studies of opioids other than morphine are positive, but 
most of them are very small studies or case series only. The few randomised trials fail to 
confirm benefit and well designed, adequately powered studies are needed in order to answer 
this question. 
 
Archived at Flinders University: dspace.flinders.edu.au
10 
 
Oxycodone is an interesting opioid in that it has kappa as well as mu activity. Whether this 
translates into additional benefit for people with dyspnoea, in terms of efficacy or safety, is 
unknown. There is a double-blind, parallel arm trial randomising participants with refractory 
breathlessness to receive morphine, oxycodone or placebo to steady state open in Australia 
(ACTRN12609000806268), but more comparative research is needed. In people with New 
York Heart Association Class III/IV heart failure, an adequately powered comparative 
crossover study with oxycodone, morphine and placebo failed to demonstrate any superiority 
of any intervention of any arm, although all improved breathlessness including placebo 
(ISRCTN85268059)(53). 
 
2. Can we define particular subgroups of people for whom opioids are more beneficial?  
  
It is clear that not all patients benefit from opioids for chronic breathlessness. The correlation 
between baseline dyspnoea severity and response to opioids was assessed in the study of 
20mg daily modified release morphine for refractory breathlessness (26). This was an 
exploratory study that was not powered to define predictors of response, but younger age, 
better performance status and cardiovascular pathology were cited as worthy of further 
prospective evaluation in a larger trial.  The “dypnoea target”,  a model of opioid 
responsiveness, has been suggested as a conceptual approach in the selection of patients for 
opioid treatment as part of their breathlessness management, in an attempt to incorporate 
factors that may influence opioid responsiveness in an individual, but this has yet to be tested 
(54).  Clearly more work is needed to identify patients most likely to benefit from opioids, 
with the lowest likelihood for toxicity. 
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The majority of people in the studies described above had breathlessness due to chronic 
obstructive pulmonary disease or cancer; very few participants had cardiac disease. There is 
one reported pilot study of repeat dose morphine in heart failure patients that found a 
statistically significant improvement in breathlessness in the morphine arm (21). Although 
the powered study in CHF(53) did not show any advantage of opioids over placebo at four 
days, an open label, patient choice three month extension showed improvement  in  
breathlessness in those who chose to continue opioids compared with those who did not. 
Indeed, those who did not had a slight deterioration in breathlessness severity 
 
3. What is the true role of opioids in the relief of breathlessness in clinical practice? 
 
Apart from the dose ranging study, the majority of data tells us about efficacy rather than the 
effectiveness in daily practice. The lack of effectiveness data to support the widespread 
implementation of opioids into primary, secondary and tertiary clinical practice is perhaps the 
most dangerous challenge to this body of science, particularly in palliative care and oncology, 
specialties renowned for its early adopters (55). There is an urgent need for phase IV 
pharmacovigilance comparative studies to give us vital information, not only about the 
differential effectiveness of various opioids, but also their side effects and impact of daily 
living when translated into the “real world” of people outside carefully controlled eligibility 
criteria. 
 
4. What is the role of other routes of administration such as intranasal, buccal, 
transdermal or nebulised? 
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There are no studies randomising participants to receive sustained-release opioids versus 
immediately available preparations. We do not know whether transdermal preparations are 
helpful for breathlessness. We do not know whether patients with stable, predictable 
breathlessness would gain more benefit from sustained-release preparations, and those with 
episodic (which could be predictable or unpredictable) breathlessness gain more benefit from 
newer delivery systems for rapid-onset such as transmucosal, buccal, nasal or inhaled 
opioids.   
 
5. What other opioid mechanisms help to ameliorate breathlessness? 
 
As discussed above, the exploration of the mechanisms involved in opioid induced benefit in 
terms of both central and peripheral mechanisms is only just beginning. As patients with 
pathological breathlessness may tolerate fMRI poorly, different methods of investigating 
brain activity could be explored, such as magnetoencephalography which does not require the 
patient to lie flat. Peripheral mechanisms involving the interplay between the sympathetic 
nervous system and peripheral muscles would be another interesting target for researchers. 
 
6. Are there agents that synergistically enhance the efficacy of opioids? 
 
Evidence regarding combined medicinal and pharmacological plus non-pharmacological 
interventions that incorporate opioids is generally lacking.  There is one study which shows 
that morphine and midazolam give additional benefit when administered together in 
dyspnoeic patients in the dying phase (last hours of days of life), compared with giving 
midazolam alone (56). Although morphine alone gave more relief than midazolam alone, the 
combination was still the more efficacious option. However, before putting this evidence into 
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wider practice, readers should take caution.  The study population was very late in their 
illness and the results are likely more applicable in the last few hours or days of life; for 
example, approximately 20% of those randomised died within 24 hours and  baseline levels 
of breathlessness were very severe (>7 on the Borg scale, where 5 represents severe).  
Improvements with study intervention were dramatic with reductions in Borg scores down to 
2-3 within 24 – 48 hours. This study therefore highlights another issue in breathlessness 
research - the participant population needs to be carefully defined, the outcome measure 
appropriately chosen, and the findings only applied to comparable populations. 
 A small study (n=7 people with COPD) indicated greater improvement in exercise tolerance 
with a combination of morphine and promethazine than placebo or morphine alone, but there 
was no change in Borg measures of breathlessness(57). 
 
7. What are the barriers and facilitators to opioid prescribing in breathlessness? 
 
Compared with the “barriers” work completed in opioids and pain, there is little in 
breathlessness. There are some data published as conference abstracts (58;59).  Physicians are 
frequently cautious about prescribing opioids in people with chronic respiratory disease 
unless they are imminently dying, for fear of respiratory depression or addiction. Contact 
with palliative care clinicians appears to help confidence with opioid prescribing (58). 
Respiratory therapists in one centre found this attitude frustrating as they perceived opioids to 
be a potentially beneficial intervention. These physician attitudes are not supported by the 
evidence above but appear to be strongly held in this small selected survey (58). Interestingly, 
one qualitative study reviewed the impact of the Shipman murders* on general practitioner 
prescribing of opioids for COPD in England; the highly publicised murders increased 
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clinician anxiety about prescribing opioids despite evidence to the contrary, and palliative 
administration decreased (60). 
 
Patient barriers are different from physician barriers.  In an interview study of men with heart 
failure from one area of the United Kingdom, polypharmacy and opioid fears would not 
prevent them trying opioids provided they had trust in the prescribing clinician; confidence in 
their doctor was a strong feature (61). One patient interviewed commented that his doctor 
thought that prescribing morphine was dangerous. A strong theme from this study suggested 
that this group of patients did not associate the use of opioids exclusively with death and 
dying, in contrast with previous findings in patients with cancer. A possible explanation is 
that many had had experience of being given morphine very effectively during an acute, 
frightening, painful and life threatening event such as a myocardial infarction, and seemed to 
have a much more positive view of it as something to be used if recommended by their 
clinician. Also, several respondents in the study described experience of beneficial use of 
morphine for those they knew for cancer pain, where it resulted in an improved quality of 
life.  
 
 
 
 
 
 
Recommendations for further research (questions and design):  
 
*Harold Shipman was a General Practitioner in Northwest England who was sentenced to life imprisonment for 
the murder of 15 of his patients and of one count of forging a will. The subsequent Shipman Inquiry concluded that 
he killed approximately 250 patients over 27 years with lethal doses of diamorphine. Concerns were raised in the 
Inquiry and trial about the regulation of GPs in the UK, particularly in relation to the prescription of opioids.  
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Much of what we have learnt about design from experience with opioid studies can be 
generalised to other dyspnoea and palliative care research.  
 
Baseline/definitional issues 
 
1. Description of the study population should be routine so that patient profile and 
setting can be interpreted easily and judgements made with regard to generalisability 
and applicability of results. Inclusion of ethnicity and socioeconomic status in 
baseline demographic data collection would be two very helpful measures. 
2. Baseline. Definitions of dyspnoea, and terms such as “refractory” should be agreed. 
The operational definition of “refractory dyspnoea” has been defined as that which 
persists even when all identified reversible causes have been treated. This definition 
has now been published in several trials, chapters, and opinion pieces and we 
therefore recommend that this be the one used (20;62-64); importantly when using 
the same definition in different studies similar patient populations were enrolled with 
respect to intensity of breathlessness, chronicity, and aetiology even in different 
countries. Consistency across trials ensures that studies can be combined and 
compared. 
3. The concept of “total dyspnoea” appears to be a useful one and is gaining credence in 
both clinical and research communities (12;65). It also seems to have a physiological 
basis in the perception of breathlessness. This, coupled with the other concept of a 
“dyspnoea target”, which also recognises fear and anxiety as major drivers of 
breathlessness in subgroups of people, underlines the importance of designing studies 
with mixed methods.  Recent systematic reviews on outcome measurement of 
breathlessness and a consensus statement both of which call for unidimensional, 
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multidimensional and qualitative assessment of the symptom reflect this stance(66-
69). 
 
 
Design issues 
1. Clarification of the primary endpoint has been a key factor. Understanding that our 
main attention should lie with the sensation of breathlessness has resulted in 
adequately powered studies(20;53).  An appreciation of the subtleties of measurement 
of the sensation of breathlessness has also been important; there appears to be a 
diurnal variation in the perception of intensity, so assessment of “present” 
breathlessness in daily measurement needs to be measured twice daily (e.g., on 
awakening and before going to bed)(20). We have also improved our understanding in 
how best to use unidimensional measures such as the numerical rating scale, the Borg 
and the visual analogue scale, choosing with much more care which tool to use for 
which population, and in what situation(66-69). Measurement of function is still an 
important but secondary endpoint.  
2. Attrition in palliative care studies unrelated to the intervention is a predictable issue. 
Methods for accounting for drop outs unrelated to the intervention and missing data 
should be planned for in sample size calculation (some studies will experience at least 
40% drop out by 4 weeks which should be planned into the sample size) (63), study 
design, and statistical analysis plans, especially for those involving longitudinal 
analyses. 
3. Meticulous adverse event monitoring is mandatory. There is a tendency in palliative 
care to make the assumption that it is not possible to make matters any worse by 
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“trying something out” (18). This is an erroneous assumption, and any clinical trial 
should come under the same scrutiny with regard to adverse events as any other (18). 
4. The sensation of breathlessness is driven by many factors, therefore randomisation is 
needed to minimise such bias in efficacy studies.  
5. Large pharmacovigilance studies and well designed observational consecutive cohorts 
within which we have meaningful prospectively collected data to draw stratified 
conclusions are invaluable for assessing many of the questions posed earlier in this 
manuscript. For example, subgroups hypothesised to be most likely to respond can be 
assessed using multivariate analyses and the multiple inputs for the “dyspnoea target” 
could be addressed. Sufficient recruitment to such cohort studies requires multi-centre 
collaboration.  
6. Well designed qualitative studies to understand clinical decision making, barriers and 
facilitators regarding the use of opioids for breathlessness, and user experience are 
needed to help inform education and dissemination of research findings, as knowledge 
of the evidence base alone is insufficient to lead to change in practice (70). 
 
Study infrastructure 
1. Recruitment methods remain an ongoing challenge, but methods outlined by 
Abernethy and others have proved their worth in successful, multinational 
interventional studies in palliative care populations (20;62). 
2. The establishment of collaborative relationship can access pooled resources, and 
provide an important way forward (15;16).  Six ongoing rigorous phase III drug trials 
in several Australian palliative care centres are recruiting well, demonstrating that 
well-funded, well-structured collaborative studies can be completed, even in frail 
palliative care populations, if clinical centres are given the research infrastructure 
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resources to contribute to large projects. A main key to success is to keep the project 
as simple and achievable as possible, with a reduction in extraneous variables (71). 
 
Research questions 
 
1. The MCID in chronic breathlessness calculated from subjective patient data is 
important, and should be one of the first aspects of the research agenda in order to 
give patient-related relevance to research outputs.  
2. There is a need to define what is meant by “episodic breathlessness related and 
unrelated to exertion” as this appears to be a particularly challenging clinical situation 
and clear definitions are needed as a first step to study design.  
3. Rapid onset opioids are an attractive therapeutic option especially for acute crises, 
although careful delivery will be required, especially in the opioid naïve person. 
4. Synergism with other approaches such as opioids with or without oxygen, 
benzodiazepines, selective serotonin reuptake inhibitors and related drugs, should be 
explored.  Similarly, opioids in conjunction with the vast array of non 
pharmacological approaches is a whole area ripe for exploration, especially using the 
“total dyspnoea” model. 
5. We have barely scratched the surface of understanding how opioids work in helping 
the sensation of breathlessness. One of the barriers to further exploration using fMRI 
is that people with breathlessness due to advanced illness find it difficult to tolerate 
MRI scanning. Novel methods are being explored to address this issue. 
 
Conclusions 
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We have achieved much in our understanding of the use of opioids for the relief of chronic 
breathlessness. Strands are coming together from work done including expanding science in 
neuroimaging, pain, heart failure, COPD and cancer. However, there is a clear warning to 
heed; in order to move forwards to answer remaining questions, we need to work together in 
collaborative groups. Those groups need to be big enough to recruit sufficient numbers of 
study participants and should include people with a range of skills including physiologists, 
neuroimagers, trial methodologists and qualitative researchers. Let us put our energy, and the 
energy of the patients who want to help us into studies that will truly further our 
understanding in this important area.  
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